“For too long, communities of color have been underrepresented in clinical trials,” said Sen. Menendez. “As COVID-19 spread across the country and disproportionately hit densely populated minority communities, it became apparent that studies on lifesaving vaccines, drugs, and treatments must include people of all ethnic and racial backgrounds. This bill will help create more diverse clinical trials to improve the health of the nation.”
“One of the many reasons communities of color have historically low vaccination rates is because they are underrepresented in the clinical trials process,” said Sen. Scott.“Too often, these clinical trials fail to recruit an adequate number of diverse participants leading to low confidence in vaccines among underrepresented groups. The DIVERSE Trials Act will help to ensure we are one step closer to bridging the racial disparity gap.”
“The disproportionate impact of the COVID-19 pandemic on communities of color has highlighted the urgent need for diverse participation in medical trials,” Dr. Ruiz said. “As a physician, I know firsthand how factors like race and associated social determinants of health can influence the effectiveness of different medications and therapies. That is why I am introducing the DIVERSE Trials Act, which will increase diversity in clinical trial participation through outreach to underrepresented populations. With this bipartisan, bicameral legislation, we will improve health outcomes and access to lifesaving vaccines, medications, and treatments.”
“As a doctor, I know firsthand how critical it is to have the most accurate data and information to provide patients with the care they need. In order to do that successfully, ensuring that clinical trials for vaccines, drugs, and treatments adequately represent all demographics is critical,” said Dr. Bucshon. “The DIVERSE Act will help promote clinical trials having proportionate representation of all communities of color as well as support education, outreach and recruitment for future clinical trials.”
The American Cancer Society Cancer Action Network (ACS-CAN), National Health Council and We Must Coalition support the legislation.
“ACS CAN is committed to reducing barriers for patients. The DIVERSE Trials Act will ensure more patients—regardless of their economic means or their geographic location—have a chance to enroll in the best treatment options available without having to bear additional costs or inconveniences,” said Lisa Lacasse, ACS CAN President. “We urge Congress to quickly take up this bill and pass it into law.”
See more
April 16, 2024
April 14, 2024
March 12, 2024